Preclinical validation using A20-deficient murine models demonstrates faithful recapitulation of PsA clinical manifestations – including arthritis, enthesitis, synovitis, and characteristic dermatological presentations – providing robust platforms for mechanistic exploration and targeted therapeutic development. The gene discussed is TNFAIP3; the disease is synovitis.